Literature DB >> 27757498

[The results of the LAP07 trial should not be misunderstood as the end of chemoradiotherapy in pancreatic cancer].

Thomas Brunner1, Emmanouil Fokas2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27757498     DOI： 10.1007/s00066-016-1058-9

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  5 in total

1.  Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer.

Authors:  Anand Mahadevan; Rebecca Miksad; Michael Goldstein; Ryan Sullivan; Andrea Bullock; Elizabeth Buchbinder; Douglas Pleskow; Mandeep Sawhney; Tara Kent; Charles Vollmer; Mark Callery
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-12       Impact factor: 7.038

2.  Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

Authors:  Florence Huguet; Thierry André; Pascal Hammel; Pascal Artru; Jacques Balosso; Frédéric Selle; Elisabeth Deniaud-Alexandre; Philippe Ruszniewski; Emmanuel Touboul; Roberto Labianca; Aimery de Gramont; Christophe Louvet
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

3.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Authors:  Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

4.  Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.

Authors:  Pascal Hammel; Florence Huguet; Jean-Luc van Laethem; David Goldstein; Bengt Glimelius; Pascal Artru; Ivan Borbath; Olivier Bouché; Jenny Shannon; Thierry André; Laurent Mineur; Benoist Chibaudel; Franck Bonnetain; Christophe Louvet
Journal:  JAMA       Date:  2016-05-03       Impact factor: 56.272

5.  Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.

Authors:  Jack P Wang; Chen-Yi Wu; Yi-Cheng Yeh; Yi-Ming Shyr; Ying-Ying Wu; Chen-Yu Kuo; Yi-Ping Hung; Ming-Huang Chen; Wei-Ping Lee; Jiing-Chyuan Luo; Yee Chao; Chung-Pin Li
Journal:  Oncotarget       Date:  2015-07-20
  5 in total
  1 in total

1.  Nonmetastatic pancreatic cancer : Improved survival with chemoradiotherapy > 40 Gy after systemic treatment.

Authors:  Sebastian Bachmayer; Gerd Fastner; Andrea Vaszi; Wolfgang Iglseder; Peter Kopp; Josef Holzinger; Adam Dinnewitzer; Gabriel Rinnerthaler; Simon Peter Gampenrieder; Klaus Emmanuel; Richard Greil; Felix Sedlmayer; Franz Zehentmayr
Journal:  Strahlenther Onkol       Date:  2018-03-01       Impact factor: 3.621
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.